Ornibel (Ethinylestradiol, Etonogestrel)

Ethinylestradiol, the active ingredient in Ornibel, is a combined hormonal contraceptive presented as a tablet for oral use. It prevents pregnancy in women of reproductive age. GNH USA supplies Ornibel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Ornibel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ornibel is a combined hormonal contraceptive that acts on the reproductive endocrine pathway to prevent pregnancy. - Contraception: Provides reliable prevention of ovulation and pregnancy when taken as prescribed. - Menstrual cycle regulation: Helps to establish a more predictable menstrual bleeding pattern. - Acne management: Reduces androgen‑driven skin lesions in women who require contraception. - Endometriosis symptom relief: Alleviates pain associated with endometrial tissue outside the uterus.

Ornibel may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild stomach upset that often improves with continued use. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: temporary swelling or discomfort. - Spotting between periods: light vaginal bleeding. - Weight fluctuation: minor changes in body weight. - Mood changes: irritability or mild mood swings.

Serious or Rare Side Effects: - Deep vein thrombosis: blood clot formation in deep veins. - Pulmonary embolism: clot migration to lung vessels. - Stroke: cerebrovascular accident due to clot or hemorrhage. - Myocardial infarction: heart attack risk, especially in smokers. - Severe allergic reaction: rash, itching, swelling, or breathing difficulty. - Liver dysfunction: jaundice or abnormal liver enzyme levels.

Before prescribing Ornibel, clinicians should evaluate individual risk factors and counsel patients on safe use. - Smoking status: avoid in women over 35 who smoke due to increased thrombotic risk. - Cardiovascular history: assess for hypertension, stroke, or clotting disorders. - Liver disease: contraindicated in active liver disease. - Migraine with aura: use with caution due to stroke risk. - Breast cancer history: avoid in current or past estrogen‑sensitive malignancies. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Ornibel can interact with several medicines that alter hormone metabolism or increase clot risk.

Major Interactions (Avoid): - Antifungal azoles (ketoconazole, itraconazole): increase estrogen levels, raising thrombosis risk. - Antiretroviral protease inhibitors (ritonavir): elevate plasma concentrations of both hormones. - St. John’s wort: reduces contraceptive effectiveness by inducing hepatic enzymes.

Moderate Interactions (Monitor Closely): - Anticonvulsants (carbamazepine, phenytoin): may lower hormone levels, decreasing efficacy. - Antibiotics (rifampicin): can diminish contraceptive effect through enzyme induction. - Diuretics (spironolactone): may increase potassium loss when combined with estrogen.